129 related articles for article (PubMed ID: 17178693)
1. Defining a noncarcinogenic dose of recombinant human parathyroid hormone 1-84 in a 2-year study in Fischer 344 rats.
Jolette J; Wilker CE; Smith SY; Doyle N; Hardisty JF; Metcalfe AJ; Marriott TB; Fox J; Wells DS
Toxicol Pathol; 2006; 34(7):929-40. PubMed ID: 17178693
[TBL] [Abstract][Full Text] [Related]
2. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety.
Vahle JL; Sato M; Long GG; Young JK; Francis PC; Engelhardt JA; Westmore MS; Linda Y; Nold JB
Toxicol Pathol; 2002; 30(3):312-21. PubMed ID: 12051548
[TBL] [Abstract][Full Text] [Related]
3. Comparing the incidence of bone tumors in rats chronically exposed to the selective PTH type 1 receptor agonist abaloparatide or PTH(1-34).
Jolette J; Attalla B; Varela A; Long GG; Mellal N; Trimm S; Smith SY; Ominsky MS; Hattersley G
Regul Toxicol Pharmacol; 2017 Jun; 86():356-365. PubMed ID: 28389324
[TBL] [Abstract][Full Text] [Related]
4. Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose.
Vahle JL; Long GG; Sandusky G; Westmore M; Ma YL; Sato M
Toxicol Pathol; 2004; 32(4):426-38. PubMed ID: 15204966
[TBL] [Abstract][Full Text] [Related]
5. Intermittent administration of parathyroid hormone (1-37) improves growth and bone mineral density in uremic rats.
Schmitt CP; Hessing S; Oh J; Weber L; Ochlich P; Mehls O
Kidney Int; 2000 Apr; 57(4):1484-92. PubMed ID: 10760084
[TBL] [Abstract][Full Text] [Related]
6. Infrequent delivery of a long-acting PTH-Fc fusion protein has potent anabolic effects on cortical and cancellous bone.
Kostenuik PJ; Ferrari S; Pierroz D; Bouxsein M; Morony S; Warmington KS; Adamu S; Geng Z; Grisanti M; Shalhoub V; Martin S; Biddlecome G; Shimamoto G; Boone T; Shen V; Lacey D
J Bone Miner Res; 2007 Oct; 22(10):1534-47. PubMed ID: 17576164
[TBL] [Abstract][Full Text] [Related]
7. Downregulation of parathyroid hormone receptor gene expression and osteoblastic dysfunction associated with skeletal resistance to parathyroid hormone in a rat model of renal failure with low turnover bone.
Iwasaki-Ishizuka Y; Yamato H; Nii-Kono T; Kurokawa K; Fukagawa M
Nephrol Dial Transplant; 2005 Sep; 20(9):1904-11. PubMed ID: 15985520
[TBL] [Abstract][Full Text] [Related]
8. Osteosarcoma in Sprague-Dawley rats after long-term treatment with teriparatide (human parathyroid hormone (1-34)).
Watanabe A; Yoneyama S; Nakajima M; Sato N; Takao-Kawabata R; Isogai Y; Sakurai-Tanikawa A; Higuchi K; Shimoi A; Yamatoya H; Yoshida K; Kohira T
J Toxicol Sci; 2012; 37(3):617-29. PubMed ID: 22688001
[TBL] [Abstract][Full Text] [Related]
9. Daily treatment with human recombinant parathyroid hormone-(1-34), LY333334, for 1 year increases bone mass in ovariectomized monkeys.
Brommage R; Hotchkiss CE; Lees CJ; Stancill MW; Hock JM; Jerome CP
J Clin Endocrinol Metab; 1999 Oct; 84(10):3757-63. PubMed ID: 10523026
[TBL] [Abstract][Full Text] [Related]
10. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis.
Orwoll ES; Scheele WH; Paul S; Adami S; Syversen U; Diez-Perez A; Kaufman JM; Clancy AD; Gaich GA
J Bone Miner Res; 2003 Jan; 18(1):9-17. PubMed ID: 12510800
[TBL] [Abstract][Full Text] [Related]
11. Enhancement of experimental fracture-healing by systemic administration of recombinant human parathyroid hormone (PTH 1-34).
Alkhiary YM; Gerstenfeld LC; Krall E; Westmore M; Sato M; Mitlak BH; Einhorn TA
J Bone Joint Surg Am; 2005 Apr; 87(4):731-41. PubMed ID: 15805200
[TBL] [Abstract][Full Text] [Related]
12. Abnormal bone architecture and biomechanical properties with near-lifetime treatment of rats with PTH.
Sato M; Vahle J; Schmidt A; Westmore M; Smith S; Rowley E; Ma LY
Endocrinology; 2002 Sep; 143(9):3230-42. PubMed ID: 12193534
[TBL] [Abstract][Full Text] [Related]
13. Effect of intermittent systemic administration of recombinant parathyroid hormone (1-34) on mandibular fracture healing in rats.
Rowshan HH; Parham MA; Baur DA; McEntee RD; Cauley E; Carriere DT; Wood JC; Demsar WJ; Pizarro JM
J Oral Maxillofac Surg; 2010 Feb; 68(2):260-7. PubMed ID: 20116693
[TBL] [Abstract][Full Text] [Related]
14. ATF936, a novel oral calcilytic, increases bone mineral density in rats and transiently releases parathyroid hormone in humans.
John MR; Widler L; Gamse R; Buhl T; Seuwen K; Breitenstein W; Bruin GJ; Belleli R; Klickstein LB; Kneissel M
Bone; 2011 Aug; 49(2):233-41. PubMed ID: 21514409
[TBL] [Abstract][Full Text] [Related]
15. Effects of cyclic vs. daily treatment with human parathyroid hormone (1-34) on murine bone structure and cellular activity.
Iida-Klein A; Lu SS; Cosman F; Lindsay R; Dempster DW
Bone; 2007 Feb; 40(2):391-8. PubMed ID: 17056311
[TBL] [Abstract][Full Text] [Related]
16. Sequential treatment with intermittent low-dose human parathyroid hormone (1-34) and bisphosphonate enhances large-size skeletal reconstruction by vascularized bone transplantation.
Hashimoto T; Shigetomi M; Ohno T; Matsunaga T; Muramatsu K; Tanaka H; Sugiyama T; Taguchi T
Calcif Tissue Int; 2007 Sep; 81(3):232-9. PubMed ID: 17674071
[TBL] [Abstract][Full Text] [Related]
17. Daily treatment of aged ovariectomized rats with human parathyroid hormone (1-84) for 12 months reverses bone loss and enhances trabecular and cortical bone strength.
Fox J; Miller MA; Newman MK; Metcalfe AF; Turner CH; Recker RR; Smith SY
Calcif Tissue Int; 2006 Oct; 79(4):262-72. PubMed ID: 16969596
[TBL] [Abstract][Full Text] [Related]
18. Parathyroid hormone (1-34) increased total body bone mass in aged female rats.
Simmons HA; Pirie CM; Thompson DD; Ke HZ
J Pharmacol Exp Ther; 1998 Jul; 286(1):341-4. PubMed ID: 9655878
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and pharmacodynamics of subcutaneous recombinant parathyroid hormone (1-84) in patients with hypoparathyroidism: an open-label, single-dose, phase I study.
Clarke BL; Kay Berg J; Fox J; Cyran JA; Lagast H
Clin Ther; 2014 May; 36(5):722-36. PubMed ID: 24802860
[TBL] [Abstract][Full Text] [Related]
20. Sequential effects of chronic human PTH (1-84) treatment of estrogen-deficiency osteopenia in the rat.
Mitlak BH; Burdette-Miller P; Schoenfeld D; Neer RM
J Bone Miner Res; 1996 Apr; 11(4):430-9. PubMed ID: 8992873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
